A study presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) found that there was no clinically meaningful difference when patients with breast cancer were switched from treatment with reference filgrastim (Neupogen) to EP2006, the first FDA-approved filgrastim biosimilar (marketed as Zarxio).
A study presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) found that there was no clinically meaningful difference when patients with breast cancer were switched from treatment with reference filgrastim (Neupogen) to EP2006, the first FDA-approved filgrastim biosimilar (marketed as Zarxio).
The phase 3, randomized, double-blind registration study sought to assess the safety and efficacy of alternating treatment with EP2006 and the reference filgrastim for the prevention of severe neutropenia in patients undergoing myelosuppressive chemotherapy in the neoadjuvant setting.
The study comprised 218 patients who received the reference filgrastim or its biosimilar together with 6 cycles of chemotherapy. The patients were randomized into 4 arms; 2 arms received only 1 of the treatment products, either the EP2006 or the reference, and did not switch treatments. 2 arms received alternating treatments of the biosimilar and reference product (or vice versa) over cycles 1 to 6. The analysis compared the safety and efficacy of the 2 treatments between the pooled switched groups and the unswitched reference group over cycles 2 to 6. The researchers pre-defined a margin with a 95% confidence interval (CI), to demonstrate non-inferiority of the biosimilar product in febrile neutropenia (FN) rates between the switched an unswitched groups, for treatment cycles 2 to 6.
A total of 107 patients switched treatment, while 51 patients received the reference product in all cycles. Baseline characteristics were similar between the 2 treatment groups. The incidence of FN for the switched group was 3.4%, compared with 0% in the group that received the reference product alone (95% CI, range -9.65 to 4.96), a rate that fell within the pre-defined margin. Only 1 patient (switched group) was hospitalized due to FN. Infections were noted in 9.3% of the switched group versus 9.9% of the reference group. Treatment emergent adverse events were reported in 42.1% of patients in the switched group versus 39.2% of the reference group. Musculoskeletal and connective tissue disorders related to treatment with filgrastim were noted in 35.5% of the switched group versus 39.2% of the reference group. No patients developed anti-drug antibodies during the study period.
The researchers concluded that there was no evidence of clinically meaningful differences when patients undergoing treatment for breast cancer were switched between biosimilar filgrastim and reference filgrastim, or vice versa.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Celltrion, Samsung Bioepis Unveil New Biosimilar Data in CD, UC at ECCO 2024
February 23rd 2024At the Congress of European Crohn’s and Colitis Organisation (ECCO), Celltrion and Samsung Bioepis presented new finding from their respective biosimilar analyses, demonstrating positive safety and efficacy measures for the biosimilars as treatments for Crohn disease (CD) and ulcerative colitis (UC).
SABCS Posters Review Use of Biosimilars in New Contexts as Breast Cancer Therapy
January 17th 2024As one study presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) evaluated the use of circulating tumor DNA for response prediction after combination therapy with a trastuzumab biosimilar, another examined the efficacy of a pertuzumab biosimilar candidate.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Posters Show Efficacy for Combination Therapies With Trastuzumab Biosimilars in Breast Cancer
January 4th 2024Posters from San Antonio Breast Cancer Symposium 2023 found that combination therapies featuring trastuzumab biosimilars and other common cancer medicines were safe and effective in patients with breast cancer.